Mankind Pharma Q3 FY26 results: revenue 2,632 cr, PAT 449 cr, exceptional 83 cr

Emphasis Of MatterResults RestatedExceptional ItemEbitda Margin CompressionResults View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.5%Reaction day

₹2162.50

prior close

₹2199.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.6%-4.1% vs market

Pharmaceuticals peers, median of 155sector+0.2%-3.7% vs sector

On the reaction day the stock moved 4.1 pts less than Nifty Midcap 150 and 3.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.9

10m

-3.5

15m

-4.0

30m

-4.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.5+0.6-4.1+0.2-3.7

Next day

-3.6+0.3-3.9-0.4-3.2

-4.7+0.3-5.0-1.1-3.6

-3.6+1.8-5.5+0.7-4.3

-4.2+2.2-6.4+1.3-5.5

-3.5+2.3-5.8+1.5-5.0

-4.7+0.1-4.8+0.3-5.1

15d

+0.1+0.4-0.3-2.6+2.7

+1.9-4.0+5.9-5.1+7.0

-6.8-8.1+1.3-7.9+1.1

+4.9+1.3+3.5+0.7+4.2

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q3 FY26 standalone revenue at 2,632.68 crores, up 8% YoY; PAT at 449.47 crores versus 405.45 crores. Nine-month PAT at 1,329.04 crores, down 11% from 1,495.22 crores. Exceptional items of 83.42 crores cover new Labour Code impact and stamp duty on BSV acquisition. Acquired BSV Women's Health portfolio for 797 crores. Auditors flagged pending tax proceedings as Emphasis of Matter. Results restated due to acquisitions.

Likely market impact

Mixed results - top-line up YoY but bottom-line pressured by exceptional items. BSV acquisition adds future growth potential. Tax case overhang remains.